NanoViricides extends President Diwan and CFO Vyas employment agreements through June 2027
NanoViricides, Inc. extended the employment agreements of its President, Dr. Anil Diwan, and its Chief Financial Officer, Meeta Vyas, both effective July 1, 2026. The filing sets Dr. Diwan's base salary at $400,000 through June 30, 2027, and grants him 10,204 shares of Series A Preferred Stock vesting quarterly through June 30, 2027. The extensions keep the company's two senior executives in place, with the terms disclosed in the filing.
Key points
- Dr. Anil Diwan extended as President through June 30, 2027, at a base salary of $400,000
- Diwan granted 10,204 Series A Preferred Shares, vesting quarterly from September 30, 2026 and fully by June 30, 2027
- Diwan severance if terminated without cause: six months' salary; a $2 million term life policy is maintained for him
- Meeta Vyas extended as CFO for one year through June 30, 2027; company reimburses up to 50% of health insurance costs, capped at $2,500 per month
The filing
Written by AI on Nov 9, 2026, 10:08 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on September 29, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.